Showing results (131-140 of 453) with videos related to
Sort By:
Pageof 46
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.Oncology Letters|July 3, 2015
Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrateJuan Sepulveda-Sanchez, Ana Ramos, Amaya Hilario, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2019
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant CancersPatrick G Pilié, Carl M Gay, Lauren A Byers, et al.Current Problems in Cancer|February 19, 2017
Targeting the PD-1/PD-L1 axis in non-small cell lung cancerRajiv Kumar, Dearbhaile Collins, Saoirse Dolly, et al.Nature Reviews. Clinical Oncology|December 3, 2024
Synthetic lethal strategies for the development of cancer therapeuticsNatalie Y L Ngoi, David Gallo, Carlos Torrado, et al.Cancer Treatment and Research|November 17, 2023
Targeting ATR in Cancer MedicineCarolina Salguero, Christian Valladolid, Helen M R Robinson, et al.Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.Frontiers in Oncology|January 24, 2022
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug DevelopmentTimothy A Yap, Ira Jacobs, Elodie Baumfeld Andre, et al.Cancer Cell|December 19, 2025
Circulating tumor DNA as a biomarker in early phase clinical trialsHarold N Tan, Mitchell J Elliott, Ian M Silverman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2015
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory LymphomaJennifer R Brown, Matthew S Davids, Jordi Rodon, et al.Pageof 46